{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:50:32Z","timestamp":1783957832810,"version":"3.55.0"},"reference-count":166,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1107417"],"award-info":[{"award-number":["1107417"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015471","name":"Mater Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100015471","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Worldwide Cancer Research","award":["15-0181"],"award-info":[{"award-number":["15-0181"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Leukemias are clonal proliferative disorders arising from immature leukocytes in the bone marrow. While the advent of targeted therapies has improved survival in certain subtypes, relapse after initial therapy is a major problem. Dendritic cell (DC) vaccination has the potential to induce tumor-specific T cells providing long-lasting, anti-tumor immunity. This approach has demonstrated safety but limited clinical success until recently, as DC vaccination faces several barriers in both solid and hematological malignancies. Importantly, vaccine-mediated stimulation of protective immune responses is hindered by the aberrant production of immunosuppressive factors by cancer cells which impede both DC and T cell function. Leukemias present the additional challenge of severely disrupted hematopoiesis owing to both cytogenic defects in hematopoietic progenitors and an abnormal hematopoietic stem cell niche in the bone marrow; these factors accentuate systemic immunosuppression and DC malfunction. Despite these obstacles, several recent clinical trials have caused great excitement by extending survival in Acute Myeloid Leukemia (AML) patients through DC vaccination. Here, we review the phenotype and functional capacity of DCs in leukemia and approaches to harness DCs in leukemia patients. We describe the recent clinical successes in AML and detail the multiple new strategies that might enhance prognosis in AML and other leukemias.<\/jats:p>","DOI":"10.3390\/cancers11060875","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T02:37:40Z","timestamp":1561343860000},"page":"875","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Can Dendritic Cell Vaccination Prevent Leukemia Relapse?"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-3291","authenticated-orcid":false,"given":"Liam J.","family":"O\u2019Brien","sequence":"first","affiliation":[{"name":"Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-2432","authenticated-orcid":false,"given":"Camille","family":"Guillerey","sequence":"additional","affiliation":[{"name":"Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6512-6323","authenticated-orcid":false,"given":"Kristen J.","family":"Radford","sequence":"additional","affiliation":[{"name":"Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1007\/s00018-015-2005-0","article-title":"Human dendritic cell subsets and function in health and disease","volume":"72","author":"Mok","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/7403","article-title":"Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo","volume":"5","author":"Fernandez","year":"1999","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control","volume":"172","author":"Bottcher","year":"2018","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer\u2013dendritic cell axis defines checkpoint therapy\u2013responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The dendritic cell lineage: Ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.12888","article-title":"Human dendritic cell subsets: An update","volume":"154","author":"Collin","year":"2018","journal-title":"Immunology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1084\/jem.20092140","article-title":"Human CD141+ (BDCA-3) + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens","volume":"207","author":"Jongbloed","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1084\/jem.20100223","article-title":"The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8\u03b1+ dendritic cells","volume":"207","author":"Crozat","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.immuni.2012.10.018","article-title":"Human Inflammatory Dendritic Cells Induce Th17 Cell Differentiation","volume":"38","author":"Segura","year":"2013","journal-title":"Immunity"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semcdb.2018.02.018","article-title":"Human in vivo-differentiated monocyte-derived dendritic cells","volume":"86","author":"Segura","year":"2019","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.kint.2016.10.030","article-title":"Peritoneal macrophage heterogeneity is associated with different peritoneal dialysis outcomes","volume":"91","author":"Liao","year":"2017","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2013.09.023","article-title":"Monocyte-derived dendritic cells: Targets as potent antigen-presenting cells for the design of vaccines against infectious diseases","volume":"19","author":"Qu","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.coms.2008.06.011","article-title":"The leukemias","volume":"20","author":"Burke","year":"2008","journal-title":"Oral Maxillofac. Surg. Clin. N. Am."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: A comprehensive review and 2016 update","volume":"6","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.29271\/jcpsp.2018.02.133","article-title":"Proteomic Profile of Lymphoid Leukemia","volume":"28","author":"Almaiman","year":"2018","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/cdd.2014.89","article-title":"Regulation of hematopoietic and leukemic stem cells by the immune system","volume":"22","author":"Riether","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1126\/science.1164390","article-title":"Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells","volume":"322","author":"Colmone","year":"2008","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ccr.2014.04.015","article-title":"Leukemia propagating cells rebuild an evolving niche in response to therapy","volume":"25","author":"Duan","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","article-title":"Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment","volume":"122","author":"Mussai","year":"2013","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.intimp.2013.05.021","article-title":"Tumor-induced host immunosuppression: Special focus on CLL","volume":"17","author":"Cutucache","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1586\/17474086.2014.958464","article-title":"The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment","volume":"7","author":"Isidori","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.21147\/j.issn.1000-9604.2017.05.11","article-title":"Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia","volume":"29","author":"Tan","year":"2017","journal-title":"Chin. J. Cancer Res. = Chung-Kuo Yen Cheng Yen Chiu"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/08923973.2018.1424897","article-title":"Chemotherapy alters the increased numbers of myeloid-derived suppressor and regulatory T cells in children with acute lymphoblastic leukemia","volume":"40","author":"Salem","year":"2018","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2012.165","article-title":"Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function","volume":"27","author":"DiLillo","year":"2013","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of transforming growth factor-beta in hematologic malignancies","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.18632\/oncotarget.1504","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia","volume":"5","author":"Folgiero","year":"2014","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ni1249","article-title":"Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells","volume":"6","author":"Cavanagh","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2014-06-578880","article-title":"MDSCs: The final frontier of the microenvironment in CLL?","volume":"124","author":"Zirlik","year":"2014","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.acr.2015.04.002","article-title":"Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment","volume":"128","author":"Parker","year":"2015","journal-title":"Adv. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.leukres.2005.11.028","article-title":"Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation","volume":"30","author":"Orsini","year":"2006","journal-title":"Leuk. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1182\/blood-2002-06-1841","article-title":"Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration","volume":"101","author":"Dong","year":"2003","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e1419114","DOI":"10.1080\/2162402X.2017.1419114","article-title":"A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission","volume":"7","author":"Hsu","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood.V98.13.3750","article-title":"Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment","volume":"98","author":"Mohty","year":"2001","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00277-011-1231-2","article-title":"Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication","volume":"90","author":"Rickmann","year":"2011","journal-title":"Ann. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.4049\/jimmunol.1801184","article-title":"CD8\u03b1+ Dendritic Cells Dictate Leukemia-Specific CD8+ T Cell Fates","volume":"201","author":"Kline","year":"2018","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cyto.b.21332","article-title":"CD1c Myeloid Dendritic Cells in Myeloid Neoplasia","volume":"90","author":"Meyerson","year":"2016","journal-title":"Clin. Cytom."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/sji.12223","article-title":"Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult patients with acute myeloid leukaemia","volume":"80","author":"Derolf","year":"2014","journal-title":"Scand. J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1084\/jem.20150642","article-title":"Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses","volume":"213","author":"Lau","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0609.1990.tb00342.x","article-title":"Flow cytometric analysis of membrane CD11b, CD11c and CD14 expression in acute myeloid leukaemia: Relationships with monocytic subtypes and the concept of relative antigen expression","volume":"44","author":"Scott","year":"1990","journal-title":"Eur. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/CJI.0b013e3181b8f4ce","article-title":"Dendritic Cells (DCs) Can Be Successfully Generated from Leukemic Blasts in Individual Patients with AML or MDS: An Evaluation of Different Methods","volume":"33","author":"Kremser","year":"2010","journal-title":"J. Immunother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0198-8859(00)00111-7","article-title":"The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses","volume":"61","author":"Brouwer","year":"2000","journal-title":"Hum. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0301-472X(01)00636-1","article-title":"Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia","volume":"29","author":"Narita","year":"2001","journal-title":"Exp. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood.V97.9.2764","article-title":"Stimulation of autologous proliferative and cytotoxic T-cell responses by \u201cleukemic dendritic cells\u201d derived from blast cells in acute myeloid leukemia","volume":"97","author":"Harrison","year":"2001","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1182\/blood.V94.6.2048","article-title":"CD34+ Acute Myeloid and Lymphoid Leukemic Blasts Can Be Induced to Differentiate into Dendritic Cells","volume":"94","author":"Cignetti","year":"1999","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/sj.leu.2402335","article-title":"Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1","volume":"16","author":"Roddie","year":"2002","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.leukres.2013.04.002","article-title":"Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function","volume":"37","author":"Brady","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/blood.V93.3.780","article-title":"Dendritic Cells Derived In Vitro From Acute Myelogenous Leukemia Cells Stimulate Autologous, Antileukemic T-Cell Responses","volume":"93","author":"Choudhury","year":"1999","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1002\/(SICI)1521-4141(199908)29:08<2567::AID-IMMU2567>3.0.CO;2-S","article-title":"Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias","volume":"29","author":"Charbonnier","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.leukres.2009.01.007","article-title":"B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10\/IL-12 production and generation of Treg cells","volume":"33","author":"Ge","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3324\/haematol.2010.025924","article-title":"Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells","volume":"95","author":"Curti","year":"2010","journal-title":"Haematologica"},{"key":"ref_53","first-page":"2861","article-title":"Induction of Leukemia-specific Cytotoxic Response by Cross-Presentation of Late-Apoptotic Leukemic Blasts by Autologous Dendritic Cells of Nonleukemic Origin","volume":"62","author":"Spisek","year":"2002","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/sj.leu.2403474","article-title":"Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate","volume":"18","author":"Boissel","year":"2004","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2141.2002.03831.x","article-title":"Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+\/CD38\u2212 primitive haematopoietic progenitors","volume":"119","author":"Mohty","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2141.2003.03979.x","article-title":"Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia","volume":"120","author":"Eisendle","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_57","first-page":"596","article-title":"Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia","volume":"111","author":"Chen","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: A comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pathol-020712-163955","article-title":"The Pathogenesis of Chronic Lymphocytic Leukemia","volume":"9","author":"Zhang","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-3083.2007.02007.x","article-title":"Dendritic cell regeneration in the bone marrow of children treated for acute lymphoblastic leukaemia","volume":"66","author":"Laane","year":"2007","journal-title":"Scand. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2141.2004.04989.x","article-title":"Blood dendritic cells in patients with acute lymphoblastic leukaemia","volume":"126","author":"Mami","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.leu.2404146","article-title":"Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients","volume":"20","author":"Maecker","year":"2006","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.exphem.2005.11.004","article-title":"Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell loaded dendritic cells","volume":"34","author":"Hatakeyama","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1179\/102453312X13221316477453","article-title":"Generation of lymphocytes potentiated against leukemic lymphoblasts by stimulation using leukemic cell lysate-pulsed dendritic cells in patients with acute lymphoblastic leukemia and measurement of in vitro anti-leukemic cytotoxicity","volume":"17","author":"Lim","year":"2012","journal-title":"Hematology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.imbio.2007.11.009","article-title":"Blood dendritic cells in patients with chronic lymphocytic leukaemia","volume":"213","author":"Mami","year":"2008","journal-title":"Immunobiology"},{"key":"ref_67","first-page":"4497","article-title":"The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response","volume":"63","author":"Orsini","year":"2003","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1046\/j.1365-2141.2001.03223.x","article-title":"Functional monocyte-derived dendritic cells can be generated in chronic lymphocytic leukaemia","volume":"115","author":"Vuillier","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1365-2141.2001.03117.x","article-title":"Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern","volume":"115","author":"Rezvany","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2119\/2005-00011.Messmer","article-title":"Dendritic Cells from Chronic Lymphocytic Leukemia Patients Are Normal Regardless of Ig V Gene Mutation Status","volume":"10","author":"Messmer","year":"2004","journal-title":"Mol. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1365-2249.2001.01617.x","article-title":"Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate","volume":"126","author":"Goddard","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"46301","DOI":"10.18632\/oncotarget.10093","article-title":"Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia","volume":"7","author":"Toniolo","year":"2016","journal-title":"Oncotarget"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1365-2141.2004.04971.x","article-title":"Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: Influence of neoplastic CD19+ cells in vivo and in vitro","volume":"125","author":"Orsini","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s10330-007-0181-6","article-title":"Acute myeloid leukemia cells inhibit the differentiation and maturation of dendritic cells and induce the generation of regulatory T cells","volume":"7","author":"Wang","year":"2008","journal-title":"Chin. Ger. J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1182\/blood-2008-05-156471","article-title":"Defective homing and impaired induction of cytotoxic T cells by BCR\/ABL-expressing dendritic cells","volume":"113","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/emm.2006.9","article-title":"Impaired responses of leukemic dendritic cells derived from a human myeloid cell line to LPS stimulation","volume":"38","author":"Kim","year":"2006","journal-title":"Exp. Mol. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/14712598.2016.1196181","article-title":"Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies","volume":"16","author":"Ni","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cellimm.2012.01.002","article-title":"The road to the discovery of dendritic cells, a tribute to Ralph Steinman","volume":"273","author":"Rowley","year":"2012","journal-title":"Cell. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1073\/pnas.89.4.1468","article-title":"T-cell immunity to the joining region of p210BCR-ABL protein","volume":"89","author":"Chen","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood.V89.4.1133","article-title":"Use of Leukemic Dendritic Cells for the Generation of Antileukemic Cellular Cytotoxicity Against Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia","volume":"89","author":"Choudhury","year":"1997","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.biopha.2007.01.005","article-title":"Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia","volume":"61","author":"Westers","year":"2007","journal-title":"Biomed. Pharmacother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2013.00496","article-title":"Dendritic cell-based immunotherapy for myeloid leukemias","volume":"4","author":"Schurch","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3109\/14653249.2012.693744","article-title":"Dendritic cell vaccination in acute myeloid leukemia","volume":"14","author":"Anguille","year":"2012","journal-title":"Cytotherapy"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1349-7006.1999.tb00686.x","article-title":"Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation","volume":"90","author":"Fujii","year":"1999","journal-title":"Jpn. J. Cancer Res. Gann"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/sj.leu.2402979","article-title":"Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells","volume":"17","author":"Ossenkoppele","year":"2003","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2141.2007.06547.x","article-title":"Vaccination with autologous non-irradiated dendritic cells in patients with bcr\/abl+ chronic myeloid leukaemia","volume":"137","author":"Westermann","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/14653240600735743","article-title":"Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML","volume":"8","author":"Litzow","year":"2006","journal-title":"Cytotherapy"},{"key":"ref_90","first-page":"855","article-title":"Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts","volume":"28","author":"Li","year":"2006","journal-title":"Int. J. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2141.2006.05997.x","article-title":"Phase I\/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia","volume":"133","author":"Roddie","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"172965","DOI":"10.1155\/2011\/172965","article-title":"A rapid culture technique produces functional dendritic-like cells from human acute myeloid leukemia cell lines","volume":"2011","author":"Ning","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-018-2198-9","article-title":"A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia","volume":"67","author":"Santegoets","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0609.2008.01110.x","article-title":"Activation of autologous leukemia-specific T cells in acute myeloid leukemia: Monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells","volume":"81","author":"Draube","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/sj.leu.2403860","article-title":"Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia","volume":"19","author":"Hus","year":"2005","journal-title":"Leukemia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/leu.2008.29","article-title":"Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response","volume":"22","author":"Hus","year":"2008","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.coi.2017.06.003","article-title":"Turbocharging vaccines: Emerging adjuvants for dendritic cell based therapeutic cancer vaccines","volume":"47","author":"Saxena","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","article-title":"Dendritic Cell\u2013Based Immunotherapy: State of the Art and Beyond","volume":"22","author":"Bol","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1016\/j.vaccine.2006.01.029","article-title":"Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help","volume":"24","author":"Decker","year":"2006","journal-title":"Vaccine"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"368ra171","DOI":"10.1126\/scitranslmed.aag1298","article-title":"Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions","volume":"8","author":"Rosenblatt","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00262-002-0284-4","article-title":"Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: Evaluation of dendritic cell\u2013leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination","volume":"51","author":"Darling","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/sj.leu.2402913","article-title":"Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell\u2013tumour hybrids in B-CLL","volume":"17","author":"Kokhaei","year":"2003","journal-title":"Leukemia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00262-014-1600-5","article-title":"New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia","volume":"63","author":"Subklewe","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Wang, D., Huang, X.F., Hong, B., Song, X.T., Hu, L., Jiang, M., Zhang, B., Ning, H., Li, Y., and Xu, C. (2018). Efficacy of intracellular immune checkpoint-silenced DC vaccine. JCI Insight, 3.","DOI":"10.1172\/jci.insight.98368"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/ejh.13065","article-title":"Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients","volume":"101","author":"Palma","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_107","first-page":"1050","article-title":"Autologous peptides eluted from acute myeloid leukemia cells can be used to generate specific antileukemic CD4 helper and CD8 cytotoxic T lymphocyte responses in vitro","volume":"90","author":"Delluc","year":"2005","journal-title":"Haematologica"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.bbmt.2016.08.028","article-title":"Induction of Immune Response after Allogeneic Wilms\u2019 Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse","volume":"22","author":"Shah","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1056\/NEJMe1700833","article-title":"Imatinib Changed Everything","volume":"376","author":"Longo","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00262-011-1149-5","article-title":"Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: Effects of various adjuvants and definition of immune response criteria","volume":"61","author":"Palma","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.imbio.2006.05.013","article-title":"Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia","volume":"211","author":"Houtenbos","year":"2006","journal-title":"Immunobiology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"13824","DOI":"10.1073\/pnas.1008051107","article-title":"Induction of complete and molecular remissions in acute myeloid leukemia by Wilms\u2019 tumor 1 antigen-targeted dendritic cell vaccination","volume":"107","author":"Cools","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1084\/jem.20100348","article-title":"Superior antigen cross-presentation and XCR1 expression define human CD11c+\/CD141+; cells as homologues of mouse CD8a+ dendritic cells","volume":"207","author":"Bachem","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/eji.201546023","article-title":"Differential uptake and cross-presentation of soluble and necrotic cell antigen by human DC subsets","volume":"46","author":"Chiang","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1158\/1078-0432.CCR-15-2205","article-title":"Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells","volume":"22","author":"Schreibelt","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/CJI.0000000000000063","article-title":"A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer","volume":"38","author":"Prue","year":"2015","journal-title":"J. Immunother."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Fromm, P.D., Papadimitrious, M.S., Hsu, J.L., Van Kooten Losio, N., Verma, N.D., Lo, T.H., Silveira, P.A., Bryant, C.E., Turtle, C.J., and Prue, R.L. (2016). CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. Oncoimmunology, 5.","DOI":"10.1080\/2162402X.2016.1168555"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/CJI.0b013e31814fb2d6","article-title":"CMRF-56 immunoselected blood dendritic cell preparations activated with GM-CSF induce potent antimyeloma cytotoxic T-cell responses","volume":"30","author":"Freeman","year":"2007","journal-title":"J. Immunother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.celrep.2018.07.033","article-title":"Large-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity","volume":"24","author":"Balan","year":"2018","journal-title":"Cell Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.celrep.2018.05.068","article-title":"Notch Signaling Facilitates Generation of Cross-Presenting Classical Dendritic Cells","volume":"23","author":"Kirkling","year":"2018","journal-title":"Cell Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41551-018-0250-x","article-title":"Towards superior dendritic-cell vaccines for cancer therapy","volume":"2","author":"Saxena","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/bmt.2014.257","article-title":"Dendritic cell reconstitution is associated with relapse-free survival and acute GVHD severity in children after allogeneic stem cell transplantation","volume":"50","author":"Elze","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41409-018-0148-y","article-title":"Conventional dendritic cells are required for the cross-presentation of leukemia-specific antigen in a model of AML relapse post-BMT","volume":"53","author":"Markey","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.imbio.2006.05.021","article-title":"Targeting antigens to dendritic cells in vivo","volume":"211","author":"Tacken","year":"2006","journal-title":"Immunobiology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1084\/jem.20032220","article-title":"In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination","volume":"199","author":"Bonifaz","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1084\/jem.20021598","article-title":"Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance","volume":"196","author":"Bonifaz","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijpharm.2018.03.029","article-title":"Nanoparticles for dendritic cell-based immunotherapy","volume":"542","author":"Tran","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"842","DOI":"10.4049\/jimmunol.1101176","article-title":"Targeting Antigen to Mouse Dendritic Cells via Clec9A Induces Potent CD4 T Cell Responses Biased toward a Follicular Helper Phenotype","volume":"187","author":"Lahoud","year":"2011","journal-title":"J. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1080\/21645515.2015.1105415","article-title":"Dendritic cell targeted vaccines: Recent progresses and challenges","volume":"12","author":"Chen","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"232ra251","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e87102","DOI":"10.1172\/jci.insight.87102","article-title":"Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition","volume":"1","author":"Tullett","year":"2016","journal-title":"JCI Insight"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1016\/j.biomaterials.2012.02.036","article-title":"Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN","volume":"33","author":"Cruz","year":"2012","journal-title":"Biomaterials"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4049\/jimmunol.1401903","article-title":"Induction of Potent CD8 T Cell Cytotoxicity by Specific Targeting of Antigen to Cross-Presenting Dendritic Cells In Vivo via Murine or Human XCR1","volume":"194","author":"Hartung","year":"2015","journal-title":"J. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-17-1792","article-title":"NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome","volume":"24","author":"Griffiths","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/intimm\/dxl022","article-title":"Expression of human DEC-205 (CD205) multilectin receptor on leukocytes","volume":"18","author":"Kato","year":"2006","journal-title":"Int. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1182\/blood-2008-05-155176","article-title":"The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement","volume":"112","author":"Caminschi","year":"2008","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature07750","article-title":"Identification of a dendritic cell receptor that couples sensing of necrosis to immunity","volume":"458","author":"Sancho","year":"2009","journal-title":"Nature"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fimmu.2014.00239","article-title":"Harnessing Human Cross-Presenting CLEC9A(+)XCR1(+) Dendritic Cells for Immunotherapy","volume":"5","author":"Tullett","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s13238-013-3916-x","article-title":"Enhancement of DC-mediated anti-leukemic immunity in vitro by WT1 antigen and CpG co-encapsulated in PLGA microparticles","volume":"4","author":"Zhang","year":"2013","journal-title":"Protein Cell"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.4161\/21645515.2014.982993","article-title":"Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies","volume":"10","author":"Pyzer","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/cdd.2008.67","article-title":"The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death","volume":"15","author":"Panaretakis","year":"2008","journal-title":"Cell Death Differ."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24282","article-title":"Chronic lymphocytic leukemia (CLL)-Then and now","volume":"91","author":"Rai","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3324\/haematol.2012.063602","article-title":"Recent trends in survival of adult patients with acute leukemia: Overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups","volume":"98","author":"Pulte","year":"2013","journal-title":"Haematologica"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2007-12-129379","article-title":"Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3389\/fimmu.2018.02265","article-title":"Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time","volume":"9","author":"Bloemendal","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fonc.2018.00453","article-title":"CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors","volume":"8","author":"Filley","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2017-08-802926","article-title":"Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination","volume":"132","author":"Akahori","year":"2018","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_156","unstructured":"Grady, D. (2017). F.D.A. Approves First Gene-Altering Leukemia Treatment, Costing $475,000, New York Times."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.3389\/fimmu.2018.03176","article-title":"Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy","volume":"9","author":"Patente","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/14653240500499507","article-title":"CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system","volume":"8","author":"Zhong","year":"2006","journal-title":"Cytotherapy"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/gt.2013.80","article-title":"Interference with PD-L1\/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells","volume":"21","author":"Pen","year":"2014","journal-title":"Gene Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-04-278739","article-title":"siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells","volume":"116","author":"Hobo","year":"2010","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2217\/imt-2016-0029","article-title":"Immune checkpoint inhibitors side effects and management","volume":"8","author":"Kourie","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","article-title":"Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape","volume":"38","author":"Garg","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.prp.2018.10.021","article-title":"Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma\/leukemia","volume":"215","author":"Yang","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ejh.12228","article-title":"Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment","volume":"92","author":"Kronig","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Christiansson, L., Soderlund, S., Svensson, E., Mustjoki, S., Bengtsson, M., Simonsson, B., Olsson-Stromberg, U., and Loskog, A.S. (2013). Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055818"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/6\/875\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:00:36Z","timestamp":1760187636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/6\/875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,22]]},"references-count":166,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["cancers11060875"],"URL":"https:\/\/doi.org\/10.3390\/cancers11060875","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,22]]}}}